Search Result

Results for "

Kidney Fibrosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Aquaporin (1) Cadherin (1) Caspase (1) CaSR (3) Complement System (1) Cytochrome P450 (1) Drug Metabolite (1) DYRK (1) EGFR (1) Epigenetic Reader Domain (1) Free Fatty Acid Receptor (2) Glutathione Peroxidase (1) GPR84 (2) Histone Methyltransferase (2) Interleukin Related (1) Keap1-Nrf2 (1) MAP3K (1) MMP (2) NF-κB (1) Parasite (1) Procollagen C Proteinase (1) Reference Standards (2) Src (1) STAT (1) TGF-beta/Smad (3) TGF-β Receptor (1) TNF Receptor (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (2) Endocrinology (4) Infection (2) Inflammation/Immunology (14) Metabolic Disease (5)

By Targets:

Apoptosis (3)

Aquaporin (1)

Cadherin (1)

Caspase (1)

CaSR (3)

Complement System (1)

Cytochrome P450 (1)

Drug Metabolite (1)

DYRK (1)

EGFR (1)

Epigenetic Reader Domain (1)

Free Fatty Acid Receptor (2)

Glutathione Peroxidase (1)

GPR84 (2)

Histone Methyltransferase (2)

Interleukin Related (1)

Keap1-Nrf2 (1)

MAP3K (1)

MMP (2)

NF-κB (1)

Parasite (1)

Procollagen C Proteinase (1)

Reference Standards (2)

Src (1)

STAT (1)

TGF-beta/Smad (3)

TGF-β Receptor (1)

TNF Receptor (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (2)

Endocrinology (4)

Infection (2)

Inflammation/Immunology (14)

Metabolic Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: CFTR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P5314

OK2	EGFR STAT	Others
OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .

HY-156430

MMP-7-IN-3	MMP	Cancer
MMP-7-IN-3 is a potent and selective inhibitor of MMP-7. MMP-7-IN-3 suppresses kidney fibrosis progression in a mouse model with unilateral ureteral obstruction .

HY-155657

BT424	Src	Inflammation/Immunology
BT424 is a specific HCK inhibitor. BT424 can regulate macrophage activation and autophagy in vitro. BT424 ameliorates inflammation and kidney fibrosis in UUO model .

HY-18627A

PFI-2 hydrochloride 10+ Cited Publications (R)-PFI-2 hydrochloride	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀ value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-18938

Selonsertib Maximum Cited Publications 18 Publications Verification GS-4997	MAP3K Apoptosis	Cancer
Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC₅₀ of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.

HY-128439

BT173	DYRK	Cancer
BT173 is a potent homeodomain interacting protein kinase 2 (HIPK2) inhibitor. BT173 binds to HIPK2 and does not inhibit HIPK2 kinase activity but rather, interfered allosterically with the ability of HIPK2 to associate with Smad3. BT173 attenuates renal fibrosis through suppression of the TGF-β1/Smad3 pathway. BT173 can be studied in research for kidney diseases such as renal fibrosis .

HY-171804

Linvemastat FP-020	MMP	Inflammation/Immunology
Linvemastat (Compound FC-4) is an orally active MMP-12 inhibitor (IC₅₀: < 10  nM) with high selectivity of MMP-1, -2, -3, -7, -9, -10 and -14. Linvemastat significantly attenuates lung fibrosis in Bleomycin (HY-108345) induced unilateral lung fibrosis mice model and potently reduces kidney damage, interstitial inflammation or fibrosis in kidney fibrosis model of unilateral ureteral occlusion. Linvemastat can be used for inflammatory diseases research, such as idiopathie pulmonary fibrosis (IPF), inflammatory bowel disease (IBD) and asthma .

HY-18627

PFI-2 (R)-PFI-2	Histone Methyltransferase	Infection Inflammation/Immunology Cancer
PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC₅₀ value of 2.0 nM and (S)-PFI-2 shows inhibiting activity with IC₅₀ value of 1.0 μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis .

HY-144236

ZLD2218	Epigenetic Reader Domain	Others
Considerable studies confirmed that BRD4 inhibition ameliorated kidney injury and fibrosis ，and ZLD2218 exhibited the most potent inhibitory activity against BRD4, with the IC₅₀ value of 107 nM

HY-P6441

KP-6	β-catenin Wnt	Inflammation/Immunology
KP-6, a polypeptide, is a Wnt/β-catenin signal inhibitor. KP-6 inhibits TGF-β and blocks rush fibrosis signal path crucial in vivo. KP-6 suppresses Renal tissues damage and renal fibrosis, and reverse the course of disease of chronic kidney disease (CKD) .

HY-13102

UK-383367	Procollagen C Proteinase	Others
UK-383367 is an orally available pro-collagen C-protease inhibitor (BMP-1) with an IC₅₀ value of 44 nM. UK-383367 can reduce renal fibrosis and inflammation in chronic kidney disease (CKD) and may be used to study postoperative skin scarring .

HY-174913

Factor B-IN-5	Complement System	Metabolic Disease Inflammation/Immunology
Factor B-IN-5 is an orally active complement factor B (CFB) inhibitor. Factor B-IN-5 alleviates kidney damage in diabetes nephropathy by inhibiting the over activation of complement system and improving mitochondrial function. Factor B-IN-5 can improve renal tubulointerstitial inflammation and fibrosis. Factor B-IN-5 can be used for research on diabetic nephropathy .

HY-W996116

AZM198	Glutathione Peroxidase Cytochrome P450	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
AZM198 is a selective, orally active, and irreversible MPO inhibitor with an IC₅₀ of 15.0 nM. AZM198 has an IC₅₀ of 19 μM for CYP3A4. AZM198 has favorable lipophilicity, membrane permeability, metabolic stability, safety, and pharmacokinetic properties. AZM198 exhibits activity in improving vascular function, atherosclerotic plaques, pulmonary hypertension, kidney disease, visceral inflammatory fat deposition, ectopic fat deposition, and hepatic fibrosis .

HY-112671

CDDO-dhTFEA RTA dh404	Keap1-Nrf2 NF-κB Apoptosis	Cardiovascular Disease Inflammation/Immunology
CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB . CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats .

HY-N2013

Aristolactam I 1 Publications Verification Aristololactam; Aristolactam	Drug Metabolite Aquaporin Cadherin TGF-beta/Smad	Endocrinology Cancer
Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis .

HY-100775A

Fezagepras Setogepram; PBI-4050	Free Fatty Acid Receptor GPR84	Metabolic Disease Inflammation/Immunology
Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis . Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .

HY-W803134

(E/Z)-SIS3 free base	TGF-beta/Smad	Inflammation/Immunology
E/Z-SIS3 free base exhibits an inhibitory efficacy against smad3, exhibits an anti-fibrotic and anti-inflammatory effect through a TGF-β/smad3 signaling pathway .

HY-100775AR

Fezagepras (Standard) Setogepram (Standard); PBI-4050 (Standard)	Reference Standards Free Fatty Acid Receptor GPR84	Metabolic Disease Inflammation/Immunology
Fezagepras (Standard) is the analytical standard of Fezagepras. This product is intended for research and analytical applications. Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis . Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .

HY-109106A

Upacicalcet sodium SK-1403; AJT240; PLS240	CaSR	Endocrinology
Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .

HY-109106

Upacicalcet SK-1403 free acid; AJT240 free acid; PLS240 free acid	CaSR	Endocrinology
Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-beta/Smad	Metabolic Disease Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with ⁸⁹Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .

HY-109106B

(Rac)-Upacicalcet (Rac)-SK-1403 free acid; (Rac)-AJT240 free acid; (Rac)-PLS240 free acid	CaSR	Endocrinology
(Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .

HY-N2013R

Aristolactam I (Standard) Aristololactam (Standard); Aristolactam (Standard)	Reference Standards Caspase Apoptosis	Inflammation/Immunology
Aristolactam I (Standard) is the analytical standard of Aristolactam I. This product is intended for research and analytical applications. Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis .

HY-N2263

Skimmin 1 Publications Verification Umbelliferone glucoside	Interleukin Related TGF-β Receptor TNF Receptor Parasite	Inflammation/Immunology
Skimmin (Umbelliferone glucoside) is a major pharmacologically active and orally active molecule present in Hydrangea paniculata, a medical herb used in traditional Chinese medicine as an anti-inflammatory agent. Skimmin has renal protective activity. Skimmin can improve creatinine clearance, and reduce plasma creatinine, and kidney injuries. Skimmin has good anti-amoebic activity against the HM1:IMMS strain of Entamoeba histolytica. Skimmin has anti-cancer and neuroprotective activities. Skimmin reduces cardiac fibrosis as well as decreasing TNF-α, IL-6, IL1β, and TGFβ1 in cardiac tissues. Skimmin can be studied in research for diabetes and diabetes-related diseases .

Cat. No.	Product Name

HY-L185

Anti-Fibrosis Compound Library	1,995 compounds
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 1,995 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Anti-Fibrosis Compound Library

1,995 compounds

Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.

MCE contains 1,995 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Cat. No.	Product Name	Target	Research Area